A. Stoessl

发表

Localization of striatal and nigral tachykinin receptors in the rat

A. Stoessl, 1994, Brain Research.

Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra

S. Iversen, C. Dourish, A. Stoessl, 2004, Psychopharmacology.

Effects of ageing on tachykinin function in the basal ganglia

A. Stoessl, E. Polanski, H. Frydryszak, 1993, Brain Research.

The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia

A. Stoessl, E. Polanski, H. Frydryszak, 1993, Movement Disorders.

Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy

S. Iversen, C. Dourish, M. Martin-Iverson, 1989, Brain Research.

Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat.

A. Stoessl, H. Frydryszak, J. V. Van Kampen, 1996, European journal of pharmacology.

Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat

A. Stoessl, Elizabeth Szczutkowski, 1991, Brain Research.

Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists

S. Iversen, C. Dourish, A. Stoessl, 2004, Psychopharmacology.

Effects of ethanol in a putative rodent model of tardive dyskinesia

A. Stoessl, 1996, Pharmacology Biochemistry and Behavior.

Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes.

A. Stoessl, J. Zamecnik, J. McDonald, 1977, Prostaglandins.

Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics.

G. B. Young, T. Feasby, A. Stoessl, 1985, Stroke.

The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation

S. Iversen, C. Dourish, A. Stoessl, 2004, Psychopharmacology.

Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy

A. Stoessl, E. Polanski, 1993, Neuropharmacology.

Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders

A. Stoessl, 1989, Journal of psychopharmacology.

Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse

S. Iversen, L. Iversen, C. Dourish, 1987, Neuroscience Letters.

The NK‐3 tachykinin receptor agonist senktide elicits 5‐HT‐mediated behaviour following central or peripheral administration in mice and rats

S. Iversen, A. Stoessl, C.T. Dourish983, 1988, British journal of pharmacology.

Behavioural effects of selective tachykinin agonists in midbrain dopamine regions

A. Stoessl, Elizabeth Szczutkowski, I. Watson, 1991, Brain Research.

Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide

D. Hill, A. Stoessl, David R. Hill, 1990, Brain Research.

Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade.

A. Stoessl, 1996, Parkinsonism & related disorders.

A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease

N. Rajakumar, B. Flumerfelt, A. Stoessl, 1997, Neuroreport.

Environmental Exposures in Elderly Canadians With Parkinson’s Disease

V. Hachinski, H. Merskey, Truls Østbye, 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

Pharmacological characterization of the behavioral syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT

S. Iversen, C. Dourish, A. Stoessl, 1990, Brain Research.

Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist

N. Rajakumar, M. Brackstone, A. Stoessl, 1995, Brain Research.

Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone.

A. Stoessl, 1994, European journal of pharmacology.

Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine‐induced behaviors in the rat

N. Rajakumar, L. Laurier, A. Stoessl, 1997, Synapse.

Phosphorus 31 magnetic resonance spectroscopy in patients with Huntington disease.

P. Williamson, D. Drost, A. Malla, 1997, Archives of general psychiatry.

Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum

B. Flumerfelt, N. Rajakumar, B. Rajakumar, 1997, Neuroscience.

The Neurotensin Antagonist SR 48692 Fails to Modify the Behavioural Responses to a Dopamine D1 Receptor Agonist in the Rat

A. Stoessl, K. A. James, B. Napier, 1997, Neuropharmacology.

Antisense strategies for the treatment of neurological disease

A. Stoessl, A. Stoessl, 2001 .

Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.

A Jon Stoessl, A. Stoessl, Danielle Murray, 2013, Pharmacology & therapeutics.

Effect of electroconvulsive therapy on brain 5-HT2 receptors in major depression

V. Sossi, P. Liddle, R. Lam, 2010, British Journal of Psychiatry.

Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia

A. Stoessl, S. McCormick, A. Stoessl, 2002, Neuroscience.

Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.

A. Stoessl, Danielle K. Murray, 2013, Pharmacology & therapeutics.

Effects of neurotensin in a rodent model of tardive dyskinesia

A. Stoessl, 1995, Neuropharmacology.